-
KPT-330 (Selinexor) Experimental Workflows
2026-08-24
KPT-330 (Selinexor) connects CRM1-dependent nuclear export biology with practical oncology and osteoclast assays. This workflow-focused guide covers stock preparation, dose selection, target-engagement readouts, xenograft translation, and troubleshooting for reproducible cancer research.
-
EPZ5676: A Selective DOT1L Inhibitor Workflow
2026-08-24
EPZ5676 combines subnanomolar biochemical potency with exceptional DOT1L selectivity, making it useful for connecting H3K79 methylation inhibition to leukemia-cell phenotypes. This workflow also shows how to extend target-engagement assays toward innate immune signaling and combination studies in multiple myeloma.
-
Tunable Human Intestinal Organoids: Study Insights
2026-08-23
Yang and colleagues developed a human small intestinal organoid system that increases cellular diversity without sacrificing proliferative capacity by combining pathway modulators that strengthen stemness and differentiation potential. The study also shows that organoid fate can be reversibly shifted toward enterocytes or directed toward specific intestinal lineages, creating a practical framework for scalable organoid experimentation.
-
Merbromin: From Dye Signal to Assay Decisions
2026-08-22
Merbromin is more than a fluorescent dye: it can connect protein-binding measurements, protease inhibition, antimicrobial research, and tissue-processing decisions. This evidence-based guide shows how to select controls, interpret fluorescence changes, and recognize the compound’s practical limitations.
-
O6-Benzylguanine: MGMT Inhibitor Workflows
2026-08-22
O6-Benzylguanine provides a direct pharmacological route to suppress MGMT-mediated DNA repair and test sensitization to alkylating agents. This workflow-focused guide connects biochemical activity measurements with resistant glioma models, DNA-damage readouts, and practical troubleshooting for cancer chemotherapy research.
-
Sodium Oxamate for Reliable Cell Assays
2026-08-21
Sodium Oxamate (SKU C3893) helps researchers distinguish glycolytic suppression from genuine loss of cell viability when studying LDH-A and metabolic reprogramming. This scenario-based guide covers assay compatibility, protocol controls, interpretation, and practical vendor-selection criteria.
-
Ozone, Macrophage Efferocytosis, and Neuropathic Pain
2026-08-20
A 2024 Frontiers in Immunology study identifies macrophage efferocytosis as a mechanistic link between ozone treatment and reduced neuropathic pain in a chronic constriction injury model. Its evidence connects AMPK activation with Gas6–MerTK signaling, SOCS3 induction, and reduced inflammatory cytokine expression, while pharmacological inhibition supports pathway involvement.
-
From Approved Drugs to Mechanistic AML Discovery
2026-08-20
A mechanism-first framework for using approved-drug collections to connect phenotypic screening with causal biology, translational validation, and more disciplined AML drug repositioning.
-
CHIR-99021 Workflow for Stem Cell Signaling
2026-08-19
CHIR-99021 (CT99021) gives researchers a precise way to test GSK-3-dependent control of pluripotency, lineage commitment, and Wnt pathway activity. This workflow connects dose-and-time optimization with practical controls for cardiac, neuronal, and immune-cell applications.
-
Y-27632 Workflow for NIID iPSC Research
2026-08-19
Use Y-27632 to separate ROCK-dependent cytoskeletal phenotypes from disease-specific features in patient-derived NIID iPSCs. This practical workflow combines dose and washout experiments with stringent pluripotency, genomic, and contamination controls for more interpretable results.
-
Metformin Hydrochloride in Fibrosis Research
2026-08-18
Metformin Hydrochloride is more than a metabolic research compound: emerging evidence positions it as an AMPK-centered tool for investigating tissue fibrosis. This assay-focused analysis explains how the vocal fold injury model informs experimental design, controls, dosing interpretation, and translational limits.
-
O6-Benzylguanine and the MGMT Bottleneck
2026-08-18
O6-Benzylguanine provides a direct pharmacological route to MGMT inhibition, helping translational researchers distinguish DNA repair blockade from transcriptional regulation. By connecting MGMT inhibitor workflows with recent findings on AP-2α and temozolomide resistance, this article outlines a more rigorous strategy for cancer chemotherapy research.
-
Metal-Free Carbon Nanozymes for ALP Detection
2026-08-17
The reference study introduces metal-free carbon dots as nanozymes for a turn-on colorimetric assay of alkaline phosphatase activity. Its key advance is the kinetic identification of pyrophosphate as a noncompetitive inhibitor at a site distinct from the principal catalytic region, enabling sensitive ALP measurement without metal-based components.
-
Dibutyryl-cAMP, Sodium Salt for Brain Slice Assays
2026-08-17
Dibutyryl-cAMP, sodium salt provides a stable, cell-permeable way to perturb cAMP–PKA signaling in cultured cells and organotypic brain slices. This guide connects practical DBcAMP sodium salt workflows with tau pathology assays, neuronal metabolism, differentiation, and inflammation studies while emphasizing controls and interpretation limits.
-
7ACC2: A Causal Tool for Tumor Metabolism
2026-08-16
7ACC2 is a monocarboxylate transporter 1 inhibitor with an unusual dual impact on lactate uptake and mitochondrial pyruvate transport. This assay-first guide explains how to distinguish target engagement from downstream immunometabolic effects and design more informative cancer metabolism research workflows.